Welcome to our dedicated page for IDEAYA Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEAYA Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEAYA Biosciences's regulatory disclosures and financial reporting.
IDEAYA Biosciences, Inc. received an updated ownership report from Capital Research Global Investors, which reports beneficial ownership of 5,279,675 shares of IDEAYA common stock. This represents 6.0% of the 87,666,408 shares believed to be outstanding as of the reported date.
Capital Research Global Investors has sole power to vote and dispose of all 5,279,675 shares and no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of IDEAYA.
IDEAYA Biosciences Chief Financial Officer receives new stock option grant. On January 30, 2026, CFO Joshua Bleharski was granted a stock option to purchase 170,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.
According to the vesting terms, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences granted its Chief Scientific Officer, Michael Anthony White, a stock option covering 190,000 shares of common stock on January 30, 2026. The option has an exercise price of $32.19 per share and is held directly by him.
According to the vesting terms, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years. This schedule makes the option fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences’ Chief Medical Officer, Darrin Beaupre, reported a new stock option grant. On January 30, 2026, he received a stock option to buy 175,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.
The option vests over four years starting from January 1, 2026: 25% of the shares vest on the first anniversary, then 1/48th of the total shares vest monthly so that the grant is fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences, Inc. granted a new equity award to its Chief Commercial Officer, Stuart Dorman. On January 30, 2026, he received a stock option for 155,000 shares of common stock with an exercise price of $32.19 per share.
According to the vesting schedule, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date.
IDEAYA Biosciences President and CEO Yujiro Hata received a grant of stock options reported as of January 30, 2026. The award covers 600,000 options to buy IDEAYA common stock at an exercise price of $32.19 per share.
According to the vesting terms, 25% of the options vest on the first anniversary of January 1, 2026, and the remaining portion vests in equal monthly installments over the following three years, so the grant becomes fully vested on the fourth anniversary of that date.
IDEAYA Biosciences SVP and General Counsel Douglas B. Snyder reported routine equity awards and employee share purchases. On 05/30/2025 and 11/28/2025, he acquired 1,039 and 1,041 shares of common stock, respectively, at $16.9065 per share under the company’s Employee Stock Purchase Plan, bringing his directly held common stock to 2,080 shares.
On 01/30/2026, he received a stock option for 130,000 shares of common stock at an exercise price of $32.19. The option vests 25% on the first anniversary of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years until fully vested on the fourth anniversary.
IDEAYA Biosciences officer Andres Ruiz Briseno reported new equity awards and share acquisitions. He acquired 682 common shares on 11/29/2024 at $23.256 and 1,253 shares on 11/28/2025 at $16.9065 under the company’s Employee Stock Purchase Plan, bringing his direct holdings to 26,466 shares.
He was also granted a stock option for 80,000 shares of common stock at an exercise price of $32.19 on 01/30/2026. According to the grant terms, 25% of the option vests on the first anniversary of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following three years.
IDEAYA Biosciences filed an 8-K describing a business update and outlining key corporate objectives for 2026 that it plans to present at the 44th Annual J.P. Morgan Healthcare Conference. The company highlights plans to advance four registrational trials, including IDE849, a Phase 1 DLL3 TOP1 antibody‑drug conjugate being developed as a monotherapy in neuroendocrine cancer, and darovasertib in both pre‑metastatic and metastatic uveal melanoma. The objectives span several focus areas such as darovasertib in uveal melanoma, ADC and DNA damage response combinations, the MTAP pathway, and next‑generation therapies, along with broader corporate goals. The filing also reiterates that these plans and anticipated timelines are forward‑looking and subject to clinical, regulatory, and operational risks.
IDEAYA Biosciences, Inc. filed a current report to note that it has posted an updated corporate presentation to the investor section of its website and furnished the same presentation as Exhibit 99.1. The presentation is dated January 12, 2026 and is intended to provide summary information about the company.
The company states that this information is being furnished under a disclosure item for investor presentations, not filed, so it is not subject to certain liability provisions of the securities laws and will not be automatically incorporated into other SEC filings. The presentation includes a Safe Harbor Statement addressing forward-looking statements.